» Articles » PMID: 34149739

Raising the 'Good' Oxidants for Immune Protection

Overview
Journal Front Immunol
Date 2021 Jun 21
PMID 34149739
Citations 13
Authors
Affiliations
Soon will be listed here.
Abstract

Redox medicine is a new therapeutic concept targeting reactive oxygen species (ROS) and secondary reaction products for health benefit. The concomitant function of ROS as intracellular second messengers and extracellular mediators governing physiological redox signaling, and as damaging radicals instigating or perpetuating various pathophysiological conditions will require selective strategies for therapeutic intervention. In addition, the reactivity and quantity of the oxidant species generated, its source and cellular location in a defined disease context need to be considered to achieve the desired outcome. In inflammatory diseases associated with oxidative damage and tissue injury, ROS source specific inhibitors may provide more benefit than generalized removal of ROS. Contemporary approaches in immunity will also include the preservation or even elevation of certain oxygen metabolites to restore or improve ROS driven physiological functions including more effective redox signaling and cell-microenvironment communication, and to induce mucosal barrier integrity, eubiosis and repair processes. Increasing oxidants by host-directed immunomodulation or by exogenous supplementation seems especially promising for improving host defense. Here, we summarize examples of beneficial ROS in immune homeostasis, infection, and acute inflammatory disease, and address emerging therapeutic strategies for ROS augmentation to induce and strengthen protective host immunity.

Citing Articles

Effects of Leaf Extracts from Genetic Resource of spp. on Neuroprotection and Anti-Neuroinflammation in HT22 and in BV2 Cells.

Dong L, Choi B, Jeong H, Lee H, Liu Z, Yoon D Plants (Basel). 2024; 13(19).

PMID: 39409690 PMC: 11478504. DOI: 10.3390/plants13192820.


Fundamentals of redox regulation in biology.

Sies H, Mailloux R, Jakob U Nat Rev Mol Cell Biol. 2024; 25(9):701-719.

PMID: 38689066 DOI: 10.1038/s41580-024-00730-2.


Non-Thermal Plasma Reduces HSV-1 Infection of and Replication in HaCaT Keratinocytes In Vitro.

Sutter J, Brettschneider J, Wigdahl B, Bruggeman P, Krebs F, Miller V Int J Mol Sci. 2024; 25(7).

PMID: 38612649 PMC: 11011387. DOI: 10.3390/ijms25073839.


Intestinal microbiome and metabolome signatures in patients with chronic granulomatous disease.

Chandrasekaran P, Han Y, Zerbe C, Heller T, DeRavin S, Kreuzberg S J Allergy Clin Immunol. 2023; 152(6):1619-1633.e11.

PMID: 37659505 PMC: 11279821. DOI: 10.1016/j.jaci.2023.07.022.


Environmental, mechanistic and evolutionary landscape of antibiotic persistence.

Bollen C, Louwagie E, Verstraeten N, Michiels J, Ruelens P EMBO Rep. 2023; 24(8):e57309.

PMID: 37395716 PMC: 10398667. DOI: 10.15252/embr.202357309.


References
1.
Aviello G, Knaus U . NADPH oxidases and ROS signaling in the gastrointestinal tract. Mucosal Immunol. 2018; 11(4):1011-1023. DOI: 10.1038/s41385-018-0021-8. View

2.
Dou Y, Li C, Li L, Guo J, Zhang J . Bioresponsive drug delivery systems for the treatment of inflammatory diseases. J Control Release. 2020; 327:641-666. PMC: 7476894. DOI: 10.1016/j.jconrel.2020.09.008. View

3.
Bartesaghi S, Radi R . Fundamentals on the biochemistry of peroxynitrite and protein tyrosine nitration. Redox Biol. 2017; 14:618-625. PMC: 5694970. DOI: 10.1016/j.redox.2017.09.009. View

4.
Gennery A . Progress in treating chronic granulomatous disease. Br J Haematol. 2020; 192(2):251-264. DOI: 10.1111/bjh.16939. View

5.
Dingjan I, Verboogen D, Paardekooper L, Revelo N, Sittig S, Visser L . Lipid peroxidation causes endosomal antigen release for cross-presentation. Sci Rep. 2016; 6:22064. PMC: 4764948. DOI: 10.1038/srep22064. View